Design, radiolabeling, and biological evaluation of a novel 177Lu-AAZTA5-Carfilzomib conjugate as a proteasome-targeted theranostic agent for multiple myeloma
{{output}}
The development of proteasome-targeted radiopharmaceuticals represents a promising strategy for the treatment of multiple myeloma. In this work, a novel Carfilzomib-based radioconjugate was designed through conjugation with the hybrid chelator AAZTA5 and subse... ...
